Latest News

STAT Plus: Pharmalittle: Novartis exec sold stock before FDA announced data scandal; FDA OKs fewer new generics this year

Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing, because the oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. But what can you do? The world keeps spinning, no matter what. So on that note, please join us for a needed cup or three of stimulation — we fancy butter pecan today, if suggestions are needed — and enjoy the menu of tidbits assembled for you. Hope you have a smashing day and, as always, please do keep in touch …

An unnamed Novartis (NVS) executive sold $946,000 worth of shares less than three weeks before the Food and Drug Administration announced data from tests of its Zolgensma gene therapy were manipulated, Reuters writes. The stock sale by an executive member of the board or executive committee was disclosed in a July 19 Swiss stock exchange filing. Novartis says “the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”

Continue to STAT Plus to read the full story…

Source link

Related posts

Trump administration prepares to ban flavored e-cigarettes

Newsemia

STAT Plus: Up and down the ladder: The latest comings and goings

Newsemia

Medical News Today: Letter from the Editor: Embracing change

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy